Introduction
Lorazepam (Ativan) is a benzodiazepine which has effective anticonvulsant, anxiolytic, and amnesic actions. Its use has been suggested in hypertension of pregnancy, since a similar drug, diazepam, has been used for this. Diazepam, however, crosses the placenta quickly and may accumulate in the fetus, concentrations in cord blood being higher than maternal values.' This is associated with a high incidence of physiological depression when maternal doses exceed 30 mg, the babies being likely to have low Apgar scores, a tendency to apnoea, reluctance to feed, and impaired thermogenesis. ' Lorazepam has a half life of about 12 hours in adults, which is appreciably shorter than that of diazepam, and is predominantly metabolised to a pharmacologically inactive glucuronide. McBride et al3 reported that cord plasma concentrations of lorazepam were generally lower than the corresponding maternal concentrations, and this was confirmed by Kanto At 26 deliveries 10 ml samples of blood from a maternal vein and the umbilical vein were taken into lithium heparin; a timed urine sample was collected from each baby every day that they remained in hospital. The separated plasma and urine were kept at -20°C until analysed. Unconjugated and total lorazepam (conjugated + unconjugated) were measured by gas-liquid chromatography using a modification of the method of Greenblatt et al.5 Each baby's resting blood pressure was measured at about 12, 36, and 60 hours using a Doppler blood-flow detector, mercury sphygmomanometer, and a 5 cm paediatric cuff. Nurses recorded the Apgar score at birth, and the baby's rectal temperature was measured every four hours for 48 hours. The amount of milk that the baby took was recorded in ml in the case of bottle feeding; if the mother was breast feeding the time that the baby sucked from each breast was recorded. A baby was thought to have established satisfactory feeding if he or she could take 30 ml of milk by sucking from a bottle or could suck effectively for three minutes from each breast.
Results
Plasma concentrations of lorazepam were slightly higher in maternal than in cord blood ( Table II shows the behaviour of babies born at term. Long-tern oral treatment had little effect on the neonate apart from delay in establishing breast feeding, which was similar to the delay after elective caesarean section without other drugs. Intravenous lorazepam was similar to diazepam in reducing the Apgar score at delivery and increasing the necessity for intubation and ventilation. Both drugs were also associated with an increased incidence of neonatal hypothermia and poor suckling, which necessitated tube feeding. Among mothers given oral treatment the babies who had delayed establishment of feeding were all delivered from those receiving a mean dose of 5-5 mg/day for a mean of 22 days.
Preterm neonates whose mothers were given lorazepam had a very high incidence of depressed respiration, hypothermia, and feeding problems: this was so by whichever route the drug had been given (table III) lorazepam per 1 of cord blood, and six of these required intubation; out of 18 with cord blood concentrations below 45 tLg/l, however, only four needed intubation. This difference was significant (p < 0 05; X2 test). Neonatal resting blood pressures for the first three days of life were the same in babies from control mothers and those treated with oral lorazepam.
Discussion
We found that maternal lorazepam has some sedative effect on the neonate, despite cord blood concentrations of the drug being in general lower than corresponding maternal values. The main route of elimination in the neonate is by conjugation to lorazepam glucuronide and renal excretion. This mechanism
We emphasise that many of the mothers treated with lorazepam in our hospital had severe hypertension and certainly required some sedative and anticonvulsant agent. In our hospital no lorazepam-treated mother has developed eclampsia, whereas two women have had eclamptic fits during continuous intravenous infusions of diazepam. The effects that we observed in newborn infants could be serious in a poorly staffed obstetric unit but were not difficult to deal with in a perinatal centre with 24-hour availability of neonatal paediatricians. Of our series of 53 high-risk infants, only two died, weighing 540 g and 900 g. Probably any therapeutic regimen for severe pre-eclampsia will result in some sedation of the neonate. Nevertheless, the potent effects on the neonate demand that the use of lorazepam intravenously and before 37 weeks of Over 24 hours before feeding established.. is very slow, however, and in many babies lorazepam glucuronide may still be detectable seven days after birth. Low drug concentrations did not appear to be associated with obvious adverse effects in the baby, and sedation was apparent for only about 48 hours. The most serious adverse effect of maternal lorazepam treatment was an excess of low Apgar scores at one minute, and there appeared to be a link between high cord blood concentrations of the drug and Apgar scores below 6 at one minute, with the need for intubation and ventilation. High-dose intravenous lorazepam treatment, particularly in preterm deliveries, was also associated with hypothermia and delayed establishment of feeding. Lorazepam is not a specifically hypotensive drug, and there was no gross depression of neonatal blood pressure. Depressant effects on the baby were about the same as with diazepam, except that in preterm infants the diazepam group had slightly better Apgar scores at one minute than the lorazepam group. Mean birth weight and gestational age were greater in the preterm diazepam group than in the preterm lorazepam group, though this did not reach statistical significance. Thus the anticipated advantages of lorazepam over diazepam for the neonate were not confirmed in this study. Though lorazepam was detectable in breast milk using a sensitive assay, the amounts that a baby would ingest were so low as to be pharmacologically insignificant.
gestation should be restricted to hospitals with facilities for neonatal intensive care.
